Production and Immunogenicity Assessment of LTp50: An <i>Escherichia coli</i>-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein

Production and Immunogenicity Assessment of LTp50: An <i>Escherichia coli</i>-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein

Subunit vaccines stand as a leading approach to expanding the current portfolio of vaccines to fight against COVID-19, seeking not only to lower costs but to achieve long-term immunity against variants of concern and have the main attributes that could overcome the limitations of the current vaccine...

Full description

Bibliographic Details
Main Authors: Alejandra Wong-Arce, Omar Gonzalez-Ortega, Andrea Romero-Maldonado, Arleth Miranda-López, Mariano García-Soto, Susan Farfán-Castro, Lourdes Betancourt-Mendiola, Samaporn Teeravechyan, Kanjana Srisutthisamphan, Mauricio Comas-García, Karla I. Solís Andrade, Sergio Rosales-Mendoza
Format: Article
Language:English
Published: MDPI AG 2024-02-01
Series:Pharmaceuticals
Subjects:
linear epitopes
built-in adjuvant
humoral response
chimeric antigen
COVID-19
Online Access:https://www.mdpi.com/1424-8247/17/3/302

Internet

https://www.mdpi.com/1424-8247/17/3/302

Similar Items